Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Operating Leases: 2019-2023

Historic Operating Leases for Spyre Therapeutics (SYRE) over the last 4 years, with Mar 2023 value amounting to $3.8 million.

  • Spyre Therapeutics' Operating Leases fell 14.42% to $3.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was $3.8 million, marking a year-over-year decrease of 14.42%. This contributed to the annual value of $4.0 million for FY2022, which is 13.11% down from last year.
  • Latest data reveals that Spyre Therapeutics reported Operating Leases of $3.8 million as of Q1 2023, which was down 4.52% from $4.0 million recorded in Q4 2022.
  • Over the past 5 years, Spyre Therapeutics' Operating Leases peaked at $5.1 million during Q4 2020, and registered a low of $372,000 during Q1 2019.
  • Moreover, its 3-year median value for Operating Leases was $4.5 million (2022), whereas its average is $4.4 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Operating Leases surged by 1,194.35% in 2020, and later declined by 14.42% in 2023.
  • Quarterly analysis of 5 years shows Spyre Therapeutics' Operating Leases stood at $4.7 million in 2019, then grew by 8.85% to $5.1 million in 2020, then decreased by 10.16% to $4.6 million in 2021, then decreased by 13.11% to $4.0 million in 2022, then fell by 14.42% to $3.8 million in 2023.
  • Its Operating Leases was $3.8 million in Q1 2023, compared to $4.0 million in Q4 2022 and $4.2 million in Q3 2022.